TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29292694
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg multiunit pellet system (MUPS) tablets
Study: 29292694
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg banded capsules
Study: 22297597
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal therapy (NSPT)
Study: 24965218
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal therapy (NSPT) and Oral hygiene instructions (OHI)
Study: 17701044
Drug: Transurethral ultrasonography-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral ultrasonography-guided injections of autologous myoblasts and fibroblasts
Study: 17701044
Drug: Transurethral endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral endoscopic injections of collagen
Study: 11893435
Drug: Maternal supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal supplementation of antioxidant vitamins (beta-carotene 20 mg, vitamin E 167.8 mg, vitamin C 1000 mg daily until delivery)
Study: 9451067
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow rate (200 ml/min)
Study: 9451067
Drug: Low flow
Normalized name: high mallow flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flow rate (100 ml/min)
Study: 8560537
Drug: Oral 'conventional'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 'conventional' regimen (combination of chloramphenicol, cotrimoxazole, and doxycycline)
Study: 31345778
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg norursodeoxycholic acid
Study: 31345778
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg norursodeoxycholic acid
Study: 29896930
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (L‐[2,3,3,4,5,5,5,6,6,6‐2 H10 ]leucine at 0.15 μmol/kg fat‐free mass/min)
Study: 21028969
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg of elemental zinc daily for 8 weeks)
Study: 12008859
Drug: Anakinra 30
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra 30 to 150 mg subcutaneously each day for 24 weeks
Study: 12008859
Drug: Infliximab 3
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 3 to 10 mg/kg intravenously every 4 or 8 weeks
Study: 28536308
Drug: Melanoma peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melanoma peptide vaccine
Study: 28536308
Drug: GM-CSF and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF and/or peptide vaccine
Study: 23452375
Drug: Hydroxychloroquine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (200 to 400 mg daily for 12 months)
Study: 17149552
Drug: Lactulose 30
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose 30 ml orally 48 and 24 h prior to sigmoidoscopy, plus a single Fleet enema 2 h pre-procedure (Group 3)
Study: 8917241
Drug: Pseudoephedrine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine (30 or 60 mg)
Study: 8917241
Drug: Phenylpropanolamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylpropanolamine (20 or 37.5 mg)
Study: 18798083
Drug: Caffeine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (300 mg oral administration)
Study: 15115973
Drug: UDCA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (4 mg/kg per day)
Study: 8611058
Drug: Coping skills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coping skills therapy (with placebo)
Study: 8611058
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy (with placebo)
Study: 6347750
Drug: 3-day clotrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day clotrimazole treatment (200 mg once a day for 3 consecutive days)
Study: 6347750
Drug: 6-day clotrimazole
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-day clotrimazole treatment (100 mg once a day for 6 consecutive days)
Study: 29735467
Drug: Small dose
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small dose mifepristone
Study: 26432913
Drug: 50μg gE/AS01B
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50μg gE/AS01B formulation (HZ/su)
Study: 22898028
Drug: Domperidone gel
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone gel (1.1 mg/kg, PO, once daily)
Study: 22898028
Drug: Domperidone gel
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone gel
Study: 20714379
Drug: Farcosolvin syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Farcosolvin syrup (ambroxol 15 mg, theophylline 50 mg, guaiphenesin 30 mg per 5 mL)
Study: 20714379
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (guaiphenesin treatment)
Study: 17975955
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no laser treatment) with AH Plus cement
Study: 17975955
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no laser treatment) with EndoREZ cement
Study: 17314442
Drug: 5% topical
Normalized name: BP 5% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% topical tea tree oil gel
Study: 15036669
Drug: Flutamide 750mg
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide 750mg daily
Study: 29991347
Drug: Continue sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue sertraline
Study: 26914134
Drug: Methoxamine 2
Normalized name: methoxamine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methoxamine 2 mg alone (Group M)
Study: 26914134
Drug: Methoxamine 2
Normalized name: methoxamine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methoxamine 2 mg with atropine 0.1 mg (Group MA1)
Study: 26914134
Drug: Methoxamine 2
Normalized name: methoxamine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methoxamine 2 mg with atropine 0.2 mg (Group MA2)
Study: 26914134
Drug: Methoxamine 2
Normalized name: methoxamine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methoxamine 2 mg with atropine 0.3 mg (Group MA3)
Study: 20623289
Drug: 10 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 cc 1% Lignocaine at apical region (Group B)
Study: 20623289
Drug: 5 cc
Normalized name: Syringe Unit 35 cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 cc 1% Lignocaine at both bases (Group C)
Study: 20623289
Drug: 4 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cc at apex and 3 cc at both bases (Group D)
Study: 12496753
Drug: Semisimultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Semisimultaneous administration of midazolam (5 mg orally followed by 2 mg IV after 6 hours)
Study: 12496753
Drug: Traditional method
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional method (individual midazolam doses, 1 week apart)
Study: 9752816
Drug: CCB or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCB or ACE inhibitor as first-line therapy
Study: 7657846
Drug: Cibenzoline 260
Normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline 260 mg/day
Study: 2720134
Drug: Whole 240
Normalized name: Acetosella acetosella whole
DrugBank: Rumex acetosella whole (DB14166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole 240 mg verapamil sustained-release tablet
Study: 31525490
Drug: Child care-center
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child care-center based lessons (18-week gross motor and 12-week nutrition) administered by trained child care staff
Study: 26984901
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with Albendazole (ABZ) 15 mg/k/d for 10 days and Praziquantel (PZQ) 50 mg/k/d for 10 days
Study: 26984901
Drug: Albendazole (ABZ)
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole (ABZ) alone 15 mg/k/d for 10 days
Study: 23043965
Drug: Indirect moxibustion
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect moxibustion 2 times per week for 4 weeks (Treatment group A)
Study: 23043965
Drug: Indirect moxibustion
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect moxibustion 3 times per week for 4 weeks (Treatment group B)
Study: 16036041
Drug: Aldosterone blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone blockade (specific drug not mentioned, but refers to Aldactone and Eplerenone)
Study: 10557001
Drug: Salt restriction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt restriction diet (5 grams of sodium chloride per day) with oral and written instructions from a clinical nutritionist and provision of low sodium bread (0.5%) during weeks 4-24.
Study: 8739026
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice with quinidine sulfate (400 mg)
Study: 8739026
Drug: Water with
Normalized name: sterile water with electrolytes injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water with quinidine sulfate (400 mg)
Study: 1902054
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (Streptokinase or rt-PA)
Study: 7132728
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg) after placebo
Study: 7132728
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg) after Cimetidine
Study: 7132728
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone (25 micrograms) after placebo or Met
Study: 27046445
Drug: Trabodenoson (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabodenoson (200, 400, 800, 1,600, 2,400, or 3,200 μg)
Study: 24861853
Drug: USL255 (topiramate)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: USL255 (topiramate) extended-release capsules, single doses ranging from 25-1,400 mg
Study: 17909382
Drug: Designed delays
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Designed delays (DD) trial of reduced restrictions on Cox-2 inhibitors
Study: 16330739
Drug: Ventilation tube
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventilation tube (VT) treatment
Study: 16330739
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (no ventilation tubes)
Study: 11986409
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy (metoprolol or carvedilol)
Study: 9455713
Drug: Carbamazepine slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine slow-release formulation with food
Study: 9455713
Drug: Carbamazepine slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine slow-release formulation without food (12-hour fast)
Study: 9455713
Drug: Carbamazepine slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine slow-release formulation (both conditions)
Study: 30617388
Drug: 3% prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% prilocaine with felypressin 0.03 I.U. per ml
Study: 29433613
Drug: Indicated medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indicated medication for schizophrenia or mood disorders along with usual prayer camp activities (prayers, chain restraints and fasting)
Study: 29433613
Drug: Prayer camp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prayer camp activities alone (no medication)
Study: 23046709
Drug: Intranasal 17β
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 17β estradiol 3 mg/day for two months + 200 mg/day of micronized progesterone by vaginal route 14 days/month (E2+P)
Study: 23046709
Drug: Percutaneous 17β
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous 17β estradiol gel 1.5 mg/day for three months + 200 mg/day of micronized progesterone by vaginal route 14 days/month (E2+P)
Study: 23046709
Drug: Intranasal 17β
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 17β estradiol 3 mg/day for two months (E2)
Study: 23046709
Drug: Percutaneous 17β
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous 17β estradiol gel 1.5 mg/day for three months (E2)
Study: 19578221
Drug: Standard program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard program of intensive therapy
Study: 17804681
Drug: Recruitment to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recruitment to a clinical trial (no change in therapy)
Study: 11241092
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg intravenous methylprednisolone during sternotomy and 30 mg/kg during initiation of cardiopulmonary bypass
Study: 11241092
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg methylprednisolone at the same 2 times
Study: 11241092
Drug: Isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sodium chloride solution at the same 2 times
Study: 9706371
Drug: Idebenone 300
Normalized name: idebenone 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone 300 mg t.i.d.
Study: 9706371
Drug: Idebenone (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone (various dosages from 60 mg to 300 mg t.i.d.)
Study: 9706371
Drug: Piracetam 800
Normalized name: piracetam 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 800 mg t.i.d.
Study: 1396833
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of full length unglycosylated single‐chain‐urokinase plasminogen activator (saruplase)
Study: 277069
Drug: 10 per
Normalized name: 10 Person ANSI KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 per cent urea peroxide solution
Study: 277069
Drug: Normal oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal oral hygiene instructions
Study: 23438496
Drug: 45-g whey
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45-g whey supplement
Study: 23438496
Drug: 45-g maltodextrin
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45-g maltodextrin control
Study: 20861415
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion based on lean body weight (LBW)
Study: 20861415
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion based on total body weight (TBW)
Study: 20861415
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving propofol infusion based on total body weight (TBW)
Study: 16516954
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg alcohol dose
Study: 14739053
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (repaglinide plus pioglitazone)
Study: 7965263
Drug: Losartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (150 mg)
Study: 3111914
Drug: sorbinil (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorbinil (125 mg daily for 6 mo)
Study: 26136485
Drug: Triamcinolone hexacetonide
Normalized name: Triamcinolone Hexacetonide
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone hexacetonide (TH) 40 mg IA injection
Study: 26136485
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate (MA) 40 mg IA injection
Study: 21414223
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of autologous mononuclear bone marrow cells (mBMC)
Study: 16940835
Drug: Mebendazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole (500 mg single dose) plus iron supplements
Study: 12898818
Drug: Psychotherapy as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy as a completion of traditional treatment for vocal nodules
Study: 9952383
Drug: HBY 097
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBY 097 monotherapy (250 mg three times daily)
Study: 9952383
Drug: Zidovudine plus
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine plus HBY 097 (750 mg three times daily)
Study: 9952383
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with high‐dose HBY 097
Study: 1970427
Drug: Clozapine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (75 to 250 mg/day, mean 170.8)
Study: 6993250
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oxprenolol and hydralazine
Study: 31993819
Drug: Doxapram (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram (1 mg/kg bolus and 1 mg/kg/h infusion)
Study: 29800299
Drug: Standard 18-gauge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 18-gauge peripheral intravenous catheter
Study: 24612629
Drug: Integrated Psychological
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Psychological Intervention (IPI), including cognitive behaviour therapy for 12 months
Study: 25381560
Drug: TNFi therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFi therapy etanercept (ETN) combined with methotrexate (MTX)
Study: 25381560
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with MTX with or without additional synthetic disease modifying anti-rheumatic drugs
Study: 23006447
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2 every 21 days) plus best supportive care (BSC)
Study: 23006447
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2 every 21 days) plus BSC
Study: 21090832
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 or 80 mg/day plus amlodipine 5 or 10 mg/day
Study: 21090832
Drug: Single-pill telmisartan/amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-pill telmisartan/amlodipine
Study: 21090832
Drug: Telmisartan or
Normalized name: telmisartan Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan or amlodipine monotherapy
Study: 16166930
Drug: Azithromycin, 500
Normalized name: Azithromycin, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin, 500 mg per os 1 hour prior to the procedure
Study: 12013195
Drug: Aspirin 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 10%
Study: 12013195
Drug: Aspirin 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 1%
Study: 10413273
Drug: Higher-dose platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose platelet component (HDP)
Study: 10413273
Drug: Lower-dose platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose platelet component (LDP)
Study: 2197381
Drug: Meclofenamate 100
Normalized name: meclofenamate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclofenamate 100 mg plus codeine 60 mg
Study: 2197381
Drug: Meclofenamate 50
Normalized name: meclofenamate 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclofenamate 50 mg plus codeine 30 mg
Study: 8284070
Drug: Meclofenamate 100
Normalized name: meclofenamate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclofenamate 100 mg
Study: 6992844
Drug: 0.1% halcinonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% halcinonide cream applied three times daily
Study: 28244718
Drug: Hibiscus sabdariffa
Normalized name: HIBISCUS SABDARIFFA CALYX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hibiscus sabdariffa L. (HS) tea for 30 days
Study: 24676694
Drug: 0.035 mg
Normalized name: vanadium 0.035 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.035 mg ethinyl estradiol + 2 mg cyproterone acetate (group A)
Study: 24676694
Drug: 0.03 mg
Normalized name: biotin 0.03 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg ethinyl estradiol + 3 mg drospirenone (group B)
Study: 17938746
Drug: Dental amalgam
Normalized name: DENTAL AMALGAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental amalgam treatment
Study: 17938746
Drug: Resin composite
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin composite treatment
Study: 10225582
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin (400 mg, every 8 h)
Study: 10225582
Drug: Intravenous standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous standard therapy (beta-lactam)
Study: 10225582
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin (400 mg, every 8 h) plus beta-lactam
Study: 10225582
Drug: Intravenous standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous standard therapy (aminoglycoside plus beta-lactam)